MAP3K5 and ischemia: The effects of the ASK1 inhibitor also were linked selectively with reperfusion: Indeed, if the drug was administered late after reperfusion, the infarct-sparing effects were lost, and if the drug was administered in a model of severe ischemia without reperfusion, the infarct-sparing effect was not observed.